课题基金 / 基金详情

Novel molecular strategies for targeting Pin1 to treat cancer

Novel molecular strategies for targeting Pin1 to treat cancer
靶向 Pin1 治疗癌症的新分子策略
批准号:
2737541
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Developing new drugs to treat cancer is a high priority in clinical and pharmaceutical research. For many cancers there are no effective drugs, or existing drugs have severe side-effects which negatively impact on patient wellbeing. Therefore, there is an urgent need for the development of new medicines that work in smarter ways. This project will develop cutting-edge pharmaceuticals that target an important communication hub protein called Pin1. Pin1 is a prolyl isomerase protein that is heavily implicated in many cancer types and inhibiting its activity has been shown to be an effective therapeutic strategy. A handful of Pin1 small molecule inhibitors have been reported, but so far none have made a significant impact. This is largely due to problems associated with poor potency and selectivity. Furthermore, the molecular basis for Pin1 function is poorly understood which hampers its maturation as a drug target. This project will address these issues by investigating recently discovered cooperative dual ligand inhibition of Pin1, allosteric ligand binding effects, and consequences of Pin1 phosphorylation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
  • 批准号:
    82371616
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨成
  • 依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
  • 批准号:
    82370981
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    陈敏洁
  • 依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
  • 批准号:
    82372073
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    张淼
  • 依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
  • 批准号:
    82371652
  • 项目类别:
    面上项目
  • 资助金额:
    45.00万元
  • 批准年份:
    2023
  • 负责人:
    刘开江
  • 依托单位: